Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
An agreement between industry and authorities in effect from April last year is already having a major effect in ensuring Canadian generics prices are similar to those in other developed markets, an official report shows.
As it prepares to start injectables filings from its facility in Buena, New Jersey, Teligent is putting in place its senior operational and quality functions.
After urging the US DoJ to act against pharma companies alleged to have conspired in a price-fixing conspiracy, Bernie Sanders and Elijah Cummings write letters to Teva, Mylan and Heritage, accusing the companies of obstructing their enquiry.
A provision in new German legislation that requires insurance funds to consider a variety of suppliers will do nothing to address drug shortages because it is not obligatory, local industry association Pro Generika believes.
Teva has seen two US patents protecting the Contrave combination of naltrexone and bupropion ruled invalid on appeal. But it is no nearer bringing a generic of the weight-loss drug to market, as the Court of appeals upheld a later-expiring patent, albeit on a split decision.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.